Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael Ezekowitz

Showing results (11-20 of 49) with videos related to

Pageof 5
Sort By:
Plos One|January 16, 2020
Hypertension prevalence but not control varies across the spectrum of risk in patients with atrial fibrillation: A RE-LY atrial fibrillation registry sub-studyFinlay A McAlister, Rajibul Mian, Jonas Oldgren, et al.
Journal of the American College of Cardiology|February 25, 2012
Efficacy and safety of dabigatran compared to warfarin in patients with paroxysmal, persistent, and permanent atrial fibrillation: results from the RE-LY (Randomized Evaluation of Long-Term Anticoagulation Therapy) studyGreg Flaker, Michael Ezekowitz, Salim Yusuf, et al.
Chest|September 24, 2004
Antithrombotic therapy for coronary artery disease: the Seventh ACCP Conference on Antithrombotic and Thrombolytic TherapyRobert A Harrington, Richard C Becker, Michael Ezekowitz, et al.
The American Journal of Cardiology|November 2, 2013
Impact of atrial fibrillation in patients with ST-elevation myocardial infarction treated with percutaneous coronary intervention (from the HORIZONS-AMI [Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction] trial)A Garvey Rene, Philippe Généreux, Michael Ezekowitz, et al.
Europace : European Pacing, Arrhythmias, and Cardiac Electrophysiology : Journal of the Working Groups on Cardiac Pacing, Arrhythmias, and Cardiac Cellular Electrophysiology of the European Society of Cardiology|March 9, 2019
Reasons for hospitalization and risk of mortality in patients with atrial fibrillation treated with dabigatran or warfarin in the Randomized Evaluation of Long-term Anticoagulation Therapy (RE-LY) trialAiman Alak, Stefan H Hohnloser, Mandy Fräßdorf, et al.
Circulation|January 5, 2012
Myocardial ischemic events in patients with atrial fibrillation treated with dabigatran or warfarin in the RE-LY (Randomized Evaluation of Long-Term Anticoagulation Therapy) trialStefan H Hohnloser, Jonas Oldgren, Sean Yang, et al.
Clinical Therapeutics|July 16, 2003
Factors influencing physicians' reported use of anticoagulation therapy in nonvalvular atrial fibrillation: a cross-sectional surveyCary P Gross, Eric W Vogel, Abhay J Dhond, et al.
Heart (British Cardiac Society)|February 19, 2017
Effects of dabigatran according to age in atrial fibrillationMandy N Lauw, John W Eikelboom, Michiel Coppens, et al.
Circulation|April 13, 2016
Electrocardiographic Early Repolarization: A Scientific Statement From the American Heart AssociationKristen K Patton, Patrick T Ellinor, Michael Ezekowitz, et al.
American Heart Journal|May 13, 2015
A prospective evaluation of edoxaban compared to warfarin in subjects undergoing cardioversion of atrial fibrillation: The EdoxabaN vs. warfarin in subjectS UndeRgoing cardiovErsion of Atrial Fibrillation (ENSURE-AF) studyGregory Y H Lip, Jose Merino, Michael Ezekowitz, et al.
Pageof 5

Showing results (11-20 of 49) with videos related to

Sort By:
Pageof 5
Plos One|January 16, 2020
Hypertension prevalence but not control varies across the spectrum of risk in patients with atrial fibrillation: A RE-LY atrial fibrillation registry sub-studyFinlay A McAlister, Rajibul Mian, Jonas Oldgren, et al.
Journal of the American College of Cardiology|February 25, 2012
Efficacy and safety of dabigatran compared to warfarin in patients with paroxysmal, persistent, and permanent atrial fibrillation: results from the RE-LY (Randomized Evaluation of Long-Term Anticoagulation Therapy) studyGreg Flaker, Michael Ezekowitz, Salim Yusuf, et al.
Chest|September 24, 2004
Antithrombotic therapy for coronary artery disease: the Seventh ACCP Conference on Antithrombotic and Thrombolytic TherapyRobert A Harrington, Richard C Becker, Michael Ezekowitz, et al.
The American Journal of Cardiology|November 2, 2013
Impact of atrial fibrillation in patients with ST-elevation myocardial infarction treated with percutaneous coronary intervention (from the HORIZONS-AMI [Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction] trial)A Garvey Rene, Philippe Généreux, Michael Ezekowitz, et al.
Europace : European Pacing, Arrhythmias, and Cardiac Electrophysiology : Journal of the Working Groups on Cardiac Pacing, Arrhythmias, and Cardiac Cellular Electrophysiology of the European Society of Cardiology|March 9, 2019
Reasons for hospitalization and risk of mortality in patients with atrial fibrillation treated with dabigatran or warfarin in the Randomized Evaluation of Long-term Anticoagulation Therapy (RE-LY) trialAiman Alak, Stefan H Hohnloser, Mandy Fräßdorf, et al.
Circulation|January 5, 2012
Myocardial ischemic events in patients with atrial fibrillation treated with dabigatran or warfarin in the RE-LY (Randomized Evaluation of Long-Term Anticoagulation Therapy) trialStefan H Hohnloser, Jonas Oldgren, Sean Yang, et al.
Clinical Therapeutics|July 16, 2003
Factors influencing physicians' reported use of anticoagulation therapy in nonvalvular atrial fibrillation: a cross-sectional surveyCary P Gross, Eric W Vogel, Abhay J Dhond, et al.
Heart (British Cardiac Society)|February 19, 2017
Effects of dabigatran according to age in atrial fibrillationMandy N Lauw, John W Eikelboom, Michiel Coppens, et al.
Circulation|April 13, 2016
Electrocardiographic Early Repolarization: A Scientific Statement From the American Heart AssociationKristen K Patton, Patrick T Ellinor, Michael Ezekowitz, et al.
American Heart Journal|May 13, 2015
A prospective evaluation of edoxaban compared to warfarin in subjects undergoing cardioversion of atrial fibrillation: The EdoxabaN vs. warfarin in subjectS UndeRgoing cardiovErsion of Atrial Fibrillation (ENSURE-AF) studyGregory Y H Lip, Jose Merino, Michael Ezekowitz, et al.
Pageof 5